Table 2.
Medicare Part D Public Use File – Urologist Use of Abiraterone and Enzalutamide by Practice Type
| Abiraterone | 2013 | 2014 | 2015 | ||||||
| Total (n=98) | Moderate (n=95) | High (n=3) | Total (n=289) | Moderate (n=278) | High (n=11) | Total (n=312) | Moderate (n=301) | High (n=11) | |
| Solo | 15 | 15 | 0 | 42 | 42 | 0 | 50 | 50 | 0 |
| Single- specialty |
72 | 70 | 2 | 198 | 188 | 10 | 208 | 198 | 10 |
| Specialty | 0 | 0 | 0 | 5 | 5 | 0 | 6 | 6 | 0 |
| Multi-specialty | 11 | 10 | 1 | 44 | 43 | 1 | 48 | 47 | 1 |
| Enzalutamide | 2013 | 2014 | 2015 | ||||||
| Total (n=22) | Moderate (n=21) | High (n=1) | Total (n=87) | Moderate (n=82) | High (n=5) | Total (n=479) | Moderate (n=463) | High (n=16) | |
| Solo | 4 | 4 | 0 | 13 | 13 | 0 | 83 | 83 | 0 |
| Single- specialty |
14 | 13 | 1 | 63 | 60 | 3 | 326 | 311 | 15 |
| Specialty | 0 | 0 | 0 | 1 | 1 | 0 | 4 | 4 | 0 |
| Multi-specialty | 4 | 4 | 0 | 10 | 8 | 2 | 66 | 65 | 1 |
Moderate prescribers prescribed > 10 prescriptions in a year for abiraterone or enzalutamide but to 10 or fewer beneficiaries total. High prescribers prescribed abiraterone or enzalutamide to greater than 10 beneficiaries total in the year. Solo (1–2 physicians total); Single-specialty (>2 physicians and >50% urologists); Specialty (< 50% urologists and no primary care provider); Multi-specialty (< 50% urologists and >1 primary care provider such as internal medicine, family practice, geriatrics). Practice type for urologists who were prescribers in 2016 was not available, so only practice types for those urologists prescribing these drugs in 2013–2015 is shown here.